First Tracks Biotherapeutics, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
First Tracks Biotherapeutics completed separation from AnaptysBio on April 20, 2026. The company reported cash and investments of $168.0M as of June 30, 2026 (down from $311.6M at year-end 2025 due to combined pre-spinoff period costs). ANB033 CD122 antagonist advanced: Cohort 1 (n=30, gluten challenge) completed enrollment with Q4 2026 top-line data expected; Cohort 2 (n=40, mucosal healing) expanded and expected Q1 2027; FDA granted Fast Track designation. EoE Phase 1b ongoing with Q3 2027 data anticipated. Six-month net loss: $83.9M ($2.40/share on 35.0M shares).
Why this rating
Spinoff is administrative milestone; cash runway to Q2 2028 adequate for pipeline but burn rate ~$84M/6mo leaves limited margin. Clinical progress is routine Phase 1b execution; Fast Track is regulatory validation but not yet efficacy proof.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.